Status:
Ready to upload
Record number:
2178
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
(Council of Europe, 2018): If recent Gleason score is available, then small intra-prostatic, low-grade (Gleason score ≤ 6) tumours are considered minimal risk, intra-prostatic tumours with Gleason score 7 are considered low-to-intermediate risk and intra-prostatic(pT2c) tumours with Gleason score > 7 are considered high risk.
Histological examination of the entire prostate with a valid grading of the tumour is time-consuming and the results might not always be available before an organ is transplanted.
Donors with extra-prostatic tumour extension should be unequivocally excluded from donation and represent an unacceptable risk.
The acceptable time intervals for complete remission of historical prostate cancer are correlated to stage and Gleason grade of the tumour.
Donors with a history of curatively treated prostate cancer ≤pT2 (tumour confined to prostate) and Gleason 3 + 3 as well as donors with very small prostate cancers and Gleason 3 + 3 under ‘active surveillance’ can be accepted for organ donation as minimal transmission risk at any time after diagnosis with the prerequisite of a frequently performed and non-suspicious follow-up.
Prostate cancer confined to the prostate and Gleason grade 7 or less after curative treatment and cancer-free period > 5 years is considered minimal risk.
Higher stages and higher Gleason grades require an individual risk assessment.
A history of extra-prostatic tumour extension poses a high risk for transmission.
Time to detection:
3 months post liver transplant
Alerting signals, symptoms, evidence of occurrence:
Ultrasound at 3 months showed 3 nodular lesions in the hepatic allograft. Biopsy consistent with prostate adenocarcinoma.
Demonstration of imputability or root cause:
No evidence of primary prostate disease in the recipient. It is stated that "donor's origin was identified using molecular biology".
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Keywords:
References:
Suggest new keywords:
Malignancy
Case Report
Deceased donor
Liver transplant
Liver recipient
Prostate adenocarcinoma/carcinoma
Therapy discussed
Suggest references:
Sánchez-Montes C, Aguilera V, Prieto M, García-Campos M, Artés J, Pons-Beltrán V, Argüello L. Periesophageal Lymph Node Metastasis of Prostate Adenocarcinoma From Liver Transplant Donor. Am J Gastroenterol. 2019 Mar;114(3):378. doi: 10.14309/ajg.0000000000000135. PMID: 30840603.
Note:
Uploaded MN 5/8/22; note patient probably included in series by Mahillo et al record 2153 (CLFF: yes)
First review CLFF 6/7/22
Second review MN 1/29/23
Expert comments for publication:
The lesions stabilized with hormone therapy and chemotherapy not further specified. At 3 years, right hepatectomy was performed. One year later, tumor was also found in a periesophageal lymph node. It is noted that this case is inlcuded in the recent report of the Spanish Registry (NOTIFY record #2153; B. Mahillo, S. Martin, E. Molano, A. Navarro, P. Castro, T. Pont, et al., Malignancies in Deceased Organ Donors: The Spanish Experience; Transplantation 2022 Vol. 106 Issue 9 Pages 1814-1823) and from this we know that the donor was a 74 year old male and the recipient was alive at the time of that report with 53 month followup.